In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness. This includes progressive structural brain changes, cognitive and functional decline, poorer treatment response and an increasing vulnerability to relapse with chronicity. The underlying molecular mechanisms of neuroprogression are thought to include neurotrophins and regulation of neurogenesis and apoptosis, neurotransmitters, inflammatory, oxidative and nitrosative stress, mitochondrial dysfunction, cortisol and the hypothalamic-pituitary-adrenal axis, and epigenetic influences. Knowledge of the involvement of each of these pathways implies that specific agents that act on some or multiple of these pathways may thus block this cascade and have neuroprotective properties. This paper reviews the potential of the most promising of these agents, including lithium and other known psychotropics, aspirin, minocycline, statins, N-acetylcysteine, leptin and melatonin. These agents are putative neuroprotective agents for schizophrenia and mood disorders.
Introduction
Many individuals with major neuropsychiatric disorders such as depression, bipolar disorder and schizophrenia demonstrate illness characteristics consistent with neuroprogression. These illness characteristics include progressive structural brain changes, cognitive and functional decline, poorer treatment response and an increasing vulnerability to relapse with chronicity. Alterations in the inflammatory and immune systems have been documented to occur from the earliest stages of schizophrenia, and have been associated with neurodevelopmental changes (Altamura et al., 2013-this issue) . Many mental illnesses are associated with changes in brain morphometry, typically with reduced overall brain volume. In addition, different disorders demonstrate specific patterns of morphologic change. For example, major depression has been associated with volumetric abnormalities in cortico-striatalpallidal-thalamic (CSPT) circuits (Bora et al., 2011d) and grey matter reductions in the rostral anterior cingulate cortex (Bora et al., 2011a) . Bipolar disorder has been associated with grey matter reduction in the anterior limbic region (Bora et al., 2010) and ventricular enlargement (Strakowski et al., 2002) . People with schizophrenia show greater dorsomedial and dorsolateral prefrontal cortex grey matter reductions compared to those with bipolar disorder (Bora et al., 2011b) . Changes in brain morphometry have also been recorded in individuals with obsessive compulsive disorder (Fontenelle et al., 2009 ), post-traumatic stress disorder (Thomaes et al., 2010) and borderline personality disorder (Brunner et al., 2010) . Morphometric changes may vary with gender (Bora et al., 2011c) and duration of illness (Takahashi et al., 2009) . In schizophrenia and bipolar disorder, these changes are first evident in the ultra-high risk period, and are expressed by the first episode (Bechdolf et al., 2012) . This demonstrates that neurotoxic processes leading to morphological changes are occurring with major mental illnesses and suggest that these processes may commence prior to illness onset and continue with illness progression. Sanches et al. Abbreviations: IO and NS, inflammatory, oxidative and nitrosative stress; CSPT, corticostriatal-pallidal-thalamic; IL, interleukin; TNF-α, tumour necrosis factor alpha; TRYCAT, tryptophan-catabolite; IFN-γ, interferon-gamma; Apo-E, Apolipoprotein-E; NAC, Nacetylcysteine; ERK, extracellular signal-regulated kinase; MAP, mitogen-activated protein kinase; NO, nitric oxide; GSK-3β, glycogen synthase kinase 3β; BDNF, Brain derived neurotrophic factor; GDNF, Glial cell line-derived neurotrophic factor; IP-10, IFN-γ-inducible protein-10; CC16, Clara cell protein or uteroglobulin; sIL-1RA, soluble interleukin-1 receptor antagonist; PMA, phorbol 12-myristate 13-acetate; BAG-1, bcl-2 associated athanogene-1; EAE, experimental autoimmune encephalomyelitis; LIF-R, leukaemia inhibitory factor receptor; Bcl-2, apoptosis regulator protein; PANSS, Positive and Negative Symptoms Scale; PGE 2 , prostaglandin E2; COX-2, Cyclooxygenase-2; EPO, Erythropoietin; NAC, N-acetylcysteine; SCF, Stem cell factor; G-CSF, granulocyte-colony stimulating factor; HMG CoA, hydroxymethylglutamyl coenzyme A; TDO, tryptophan 2,3-dioxygenase; NAS, N-acetylserotonin; AANAT, arylalkylamine-N-acetyltransferase.
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